Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Company Update - Aprea Therapeutics has engaged Dr Philippe Pultar as its senior medical advisor to support the development and advancement of APR-1051, a potential best-in-class WEE1 inhibitor [1] - Dr Pultar brings extensive experience in oncology, including the development of a WEE1 inhibitor (azenosertib) from early to late-stage clinical development [2] - Dr Pultar's prior role at Zentalis Pharmaceuticals involved strategy and execution of the global clinical development of azenosertib, a WEE1 inhibitor [2] Clinical Development - Patient enrollment is ongoing in the Phase 1 ACESOT-1051 study, which assesses the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of APR-1051 in advanced solid tumors with certain cancer-associated gene alterations [3] - Aprea plans to provide an update on the progress of the ACESOT-1051 clinical study by the end of 2024 [3] - The WEE1 program is part of Aprea's portfolio of DDR-targeted therapeutics aimed at delivering precision medicine solutions [3] Leadership and Expertise - Dr Pultar has over 17 years of experience in early and late-stage clinical development, including roles at Zentalis Pharmaceuticals, Novartis Oncology, Agennix AG, and ImClone Systems [5] - Dr Pultar initiated seven Phase 1 and Phase 2 trials with azenosertib as a single agent and in combination with chemotherapy and targeted agents across multiple indications [5] - Dr Pultar's foundational education includes Medical Studies and Residency at Université de Médecine de Poitiers, France [6] Strategic Vision - Dr Pultar believes WEE1 inhibition is a promising therapeutic approach in oncology and is impressed by the progress of APR-1051, which has a differentiated profile and compelling pre-clinical data [4] - Aprea's President and CEO, Dr Oren Gilad, highlights Dr Pultar's track record of successfully leading programs through late-stage development and regulatory approval [4] - Dr Pultar's addition aligns with Aprea's strategy to bring in exceptional talent to advance its programs and maximize the therapeutic potential of APR-1051 [4] Leadership Transition - Dr Nadeem Mirza will step down as Chief Medical Officer effective October 9, 2024, but will remain with the company until no later than December 13, 2024, to ensure a smooth transition [4]